Mind Cure Launches Product Sales Division
Mind Cure Health (CSE: MCUR) continued its constant roll of news this week, announcing this morning that it has launched its nootropic and adaptogen products. The products are now available for purchase on the firms ecommerce platform, with shipping of products to commence next week.
The product launch marks the start of the firms sales division, with the first products to hit the market slated to target the mental hygiene and wellness segment. The first formulations consist of three noontropic formulations in both capsule and powder forms, as well as what as the firm refers to as a “teen-centric” formulation in capsule form.
The formulations are based on all-natural ingredients, utilizing various functional mushrooms, such as lion’s mane, reishi, and turkey tail, to provide healthy formulations to consumers.
“MINDCURE’s nootropic and adaptogen products are safe, unique, and packed with all-natural ingredients specifically chosen to promote mental performance. We’re eager to continue developing our product offerings to help in new and exciting ways.”
Sacha Hebbert, Senior Product & Marketing Manager
Mind Cure Health last traded at $0.61 on the CSE.
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
